Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | CCR6 | P51684 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22816525 | 0.87 | SLC6A4 (0.45) | SLC6A4SLC6A3SLC6A2CCR6KCNH2 | |
| SCHEMBL22816518 | 0.86 | SLC6A4 (0.47) | SLC6A4SLC6A3SLC6A2PTGS2 | |
| SCHEMBL22816521 | 0.85 | SLC6A4 (0.63) | SLC6A4SLC6A3SLC6A2CCR6KCNH2 | |
| SCHEMBL26394931 | 0.85 | SLC6A4 (0.48) | SLC6A4SLC6A3SLC6A2CCR6KCNH2 | |
| SCHEMBL28216814 | 0.78 | SLC6A4 (0.43) | SLC6A4SLC6A3SLC6A2CCR6KCNH2 | |
| SCHEMBL18151881 | 0.76 | SLC6A4 (0.49) | SLC6A4SLC6A3SLC6A2PTGS2KDM1A | |
| SCHEMBL1677166 | 0.76 | SLC6A4 (0.53) | SLC6A4SLC6A3SLC6A2PTGS2KDM1A | |
| SCHEMBL28888791 | 0.76 | SLC6A4 (0.49) | SLC6A4SLC6A3SLC6A2PTGS2KDM1A | |
| SCHEMBL10157208 | 0.76 | SLC6A4 (0.65) | SLC6A4SLC6A3SLC6A2PTGS2KDM1A | |
| SCHEMBL26394892 | 0.75 | SLC6A4 (0.47) | SLC6A4SLC6A3SLC6A2CCR6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414332-B1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022069-A1 | ACRYLAMIDE COMPOUNDS AND THE USE THEREOF | TRPA1, TRPV1, CACNA1B | SLC6A4 200/4885SLC6A3 711/4885SLC6A2 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.